T80.51XD: Anaphylactic reaction due to administration of blood and blood products, subsequent encounter
T80.51XD is a billable, specific ICD-10-CM code for anaphylactic reaction due to administration of blood and blood products, subsequent encounter. It is valid for submission on a claim.
Check T80.51XD with the rest of the claim: free scrubber7th character "D": subsequent encounter
The appropriate 7th character is to be added to each code from category T80
- A
- initial encounter
- D
- subsequent encounter
- S
- sequela
Excludes1 inherited from the categories above T80.51XD
A category’s note binds every code beneath it.
Written on T80.5: Anaphylactic reaction due to serum
- ABO incompatibility reaction due to transfusion of blood or blood products (T80.3-)
- allergic reaction or shock NOS (T78.2)
- anaphylactic reaction or shock NOS (T78.2)
- anaphylactic reaction or shock due to adverse effect of correct medicinal substance properly administered (T88.6)
- other serum reaction (T80.6-)
Excludes2 inherited from the categories above T80.51XD
Not part of this code, but both may be coded when both are present.
Written on T80: Complications following infusion, transfusion and therapeutic injection
- bone marrow transplant rejection (T86.01)
- febrile nonhemolytic transfusion reaction (R50.84)
- fluid overload due to transfusion (E87.71)
- posttransfusion purpura (D69.51)
- transfusion associated circulatory overload (TACO) (E87.71)
- transfusion (red blood cell) associated hemochromatosis (E83.111)
- transfusion related acute lung injury (TRALI) (J95.84)
Risk adjustment
No CMS-HCC V28 category: this code does not change a RAF score.
Medicare coverage
T80.51XD is named in 18 Medicare coverage policies: 18 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A53058Billing and Coding: Home Health Physical Therapy
- A53065Billing and Coding: Outpatient Physical Therapy
- A56538Billing and Coding: Allergen Immunotherapy
- A56558Billing and Coding: Allergy Testing
Code history
Unchanged in every release from FY2024 to FY2027.